Letters to the Editor
Drospirenone and mood
- Andrew Zuschmann, Eveline Mu, Jayashri Kulkarni
- Aust Prescr 2022;45:116
- 1 August 2022
- DOI: 10.18773/austprescr.2022.048
ISSUE 4 AUGUST
Letter
I read with interest the article ‘Hormonal contraception and mood disorders’, but noted that it overlooked the 4 mg drospirenone 24/4 progestogen-only pill (Slinda).1 The article also did not consider the 20 microgram ethinylestradiol/3 mg drospirenone preparation which has an indication for treatment of premenstrual dysphoric disorder.
Perhaps the authors might consider that the benefits shown in their pilot study may be due to a 24/4 preparation (also noted in the studies referenced in reducing pill-free interval) as well as the active ingredient?
Andrew Zuschmann
Obstetrician and gynaecologist, Anaria,
Miranda, NSW
Conflicts of interest: Dr Zuschmann has been a consultant to Bayer, Besins and MSD.
Authors' response
Eveline Mu and Jayashri Kulkarni, the authors of the article, comment:
The 4 mg drospirenone preparation became available in Australia in October 2021 after we wrote the article.1
For contraceptives containing drospirenone, a 2012 Cochrane meta-analysis tentatively described improvement in women with premenstrual dysphoric disorder, however there was a large placebo effect.2 Our clinical experience with the 20 microgram ethinylestradiol/3 mg drospirenone preparation in women with premenstrual dysphoric disorder and (commonly) a trauma history is that the lower dose ethinylestradiol, compared to many other preparations, did not improve premenstrual dysphoric disorder as well as the combination of estradiol and nomegestrol.3
The estradiol and nomegestrol combination is effective because of its 24/4 regimen. As the proposed aetiology for mood disturbance is related to the cyclical shift in endogenous estrogen, having more estradiol (24 days) is better in terms of equilibrium of both mood and estrogen. Nomegestrol is a better progestogen in terms of neurotransmitter interactions. However, a head-to-head clinical trial of a 21/7 pill compared to 24/4 needs to be done to confirm this.
References
- Mu E, Kulkarni J. Hormonal contraception and mood disorders. Aust Prescr 2022;45:75-9.
- Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012;2:CD006586.
- Biegon A, McEwen BS. Modulation by estradiol of serotonin receptors in brain. J Neurosci 1982;2:199-205.
The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by any responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Andrew Zuschmann
Obstetrician and gynaecologist, Anaria, Miranda, NSW
Eveline Mu
Postdoctoral researcher, Monash Alfred Psychiatry Research Centre, Monash University Central Clinical School and The Alfred Hospital, Melbourne
Jayashri Kulkarni
Professor of Psychiatry and Director, Monash Alfred Psychiatry Research Centre, Monash University Central Clinical School and The Alfred Hospital, Melbourne
